Clinical Study
Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients
Table 1
Comparison of patients with grade ≤2 liver injury and grade ≥3 liver injury induced by ICIs.
| | Characteristic | All grade | Grade 1 or 2 | Grade 3 or 4 | value |
| | The number of patients | 56/343 (16.3%) | 45/56 (80.4%) | 11/56 (19.6%) | | | Median age, years | 63 (49–69) | 63.0 (50–70) | 58.0 (48.0–67.0) | 0.4327 | | Sex, male | 31 (63.6%) | 24/45 (53.3%) | 7/11 (63.6%) | 0.7373 | | Previous extrahepatic irAEs | 7/56 (12.5%) | 6/45 (13.3%) | 1/11 (9.1%) | 0.4749 | | Duration of ICIs until liver injury, days | 45.5 (21–94) | 56 (26–134) | 26 (20–56) | 0.1116 | | T-Bil (mg/dl) | 0.7 (0.4–1.0) | 0.6 (0.4–0.8) | 0.8 (0.5–1.3) | 0.0871 | | AST (IU/l) | 60 (39–136) | 46 (37–87) | 321 (101–1180) | <0.001 | | ALT (IU/l) | 58 (47–129) | 53 (45–97) | 372 (228–780) | <0.001 | | ALP (IU/l) | 471 (263–857) | 431 (242–783) | 811 (436–1453) | 0.0620 | | γGTP (IU/l) | 95.5 (47–276) | 79 (38–250) | 187 (90–630) | 0.0391 | | Hepatocellular type | 11/56 (19.6%) | 5/45 (11.1%) | 6/11 (54.5%) | 0.0041 | | Cholestatic or mixed type | 34/56 (60.7%) | 29/45 (64.4%) | 5/11 (45.5%) | 0.3101 |
|
|
ICIs: immune checkpoint inhibitors; irAEs: immune-related adverse events; T-Bil: total bilirubin; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; γGTP: gamma-glutamyltransferase.
|
